Abstract
The oral delivery of functional DNA to the gastrointestinal system would constitute a desirable, noninvasive method for potentially treating a variety of diseases. The digestive process, however, remains a formidable barrier. This dilemma may be addressed by using targeted liposomes both to protect the polynucleotide and to deliver the therapeutic DNA with high tissue specificity. The present study represents the initial steps toward developing a novel gene delivery system designed to interact with the enterohepatic receptors of the small intestine. Two cholic acid esters were synthetically modified at position C(3) to incorporate a DNA-binding domain. These novel compounds were evaluated for their ability to protect DNA from the nucleases found in gastrointestinal segments. Additionally, the compounds were screened as a component of a gene delivery vector. Formulations containing the new bile salt derivatives protected DNA from degradation for more than 2 h and were capable of transfecting cultured NIH 3T3 cells.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 721-727 |
| Number of pages | 7 |
| Journal | Lipids |
| Volume | 35 |
| Issue number | 7 |
| State | Published - 2000 |
Fingerprint
ASJC Scopus subject areas
- Medicine (miscellaneous)
- Biochemistry, Genetics and Molecular Biology(all)
- Food Science
- Biochemistry
Cite this
Gastroprotection of DNA with a synthetic cholic acid analog. / Niedzinski, E. J.; Bennett, M. J.; Olson, D. C.; Nantz, M. H.
In: Lipids, Vol. 35, No. 7, 2000, p. 721-727.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Gastroprotection of DNA with a synthetic cholic acid analog
AU - Niedzinski, E. J.
AU - Bennett, M. J.
AU - Olson, D. C.
AU - Nantz, M. H.
PY - 2000
Y1 - 2000
N2 - The oral delivery of functional DNA to the gastrointestinal system would constitute a desirable, noninvasive method for potentially treating a variety of diseases. The digestive process, however, remains a formidable barrier. This dilemma may be addressed by using targeted liposomes both to protect the polynucleotide and to deliver the therapeutic DNA with high tissue specificity. The present study represents the initial steps toward developing a novel gene delivery system designed to interact with the enterohepatic receptors of the small intestine. Two cholic acid esters were synthetically modified at position C(3) to incorporate a DNA-binding domain. These novel compounds were evaluated for their ability to protect DNA from the nucleases found in gastrointestinal segments. Additionally, the compounds were screened as a component of a gene delivery vector. Formulations containing the new bile salt derivatives protected DNA from degradation for more than 2 h and were capable of transfecting cultured NIH 3T3 cells.
AB - The oral delivery of functional DNA to the gastrointestinal system would constitute a desirable, noninvasive method for potentially treating a variety of diseases. The digestive process, however, remains a formidable barrier. This dilemma may be addressed by using targeted liposomes both to protect the polynucleotide and to deliver the therapeutic DNA with high tissue specificity. The present study represents the initial steps toward developing a novel gene delivery system designed to interact with the enterohepatic receptors of the small intestine. Two cholic acid esters were synthetically modified at position C(3) to incorporate a DNA-binding domain. These novel compounds were evaluated for their ability to protect DNA from the nucleases found in gastrointestinal segments. Additionally, the compounds were screened as a component of a gene delivery vector. Formulations containing the new bile salt derivatives protected DNA from degradation for more than 2 h and were capable of transfecting cultured NIH 3T3 cells.
UR - http://www.scopus.com/inward/record.url?scp=0033868385&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033868385&partnerID=8YFLogxK
M3 - Article
C2 - 10941872
AN - SCOPUS:0033868385
VL - 35
SP - 721
EP - 727
JO - Lipids
JF - Lipids
SN - 0024-4201
IS - 7
ER -